½ÃÀ庸°í¼­
»óǰÄÚµå
1352091

¼¼°èÀÇ »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀå Æò°¡ : À¯Çüº°, µî±Þº°, Àç·áº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°, ±âȸ ¹× ¿¹Ãø(2016-2030³â)

Biocompatible Coatings Market Assessment, By Type, By Grade, By Materials, By End-user, By Region, Opportunities and Forecast, 2016-2030F

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Market Xcel - Markets and Data | ÆäÀÌÁö Á¤º¸: ¿µ¹® 141 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°è »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀå ±Ô¸ð´Â 2022³â 154¾ï ´Þ·¯¿¡¼­ 2030³â 412¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 13.1%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ýü ÀûÇÕ¼º ÄÚÆÃÀº ÇâÈÄ ¸î ³âµ¿¾È Å©°Ô ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÀÇ·á±â±â ºÎ¹®¿¡ ÇÊ¿äÇÑ ÄÚÆÃ ±â¼ú °³¹ß¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù.

Ç÷¾× ÀûÇÕ¼º ÄÚÆÃÀÇ ¼ºÀå

½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â Á¦Ç°Àº ÀÇ·á¿ë Á¦Ç°¿¡ Àû¿ëÇϱ⿡´Â Ç÷¾× ÀûÇÕ¼ºÀÌ ÃæºÐÇÏÁö ¾Ê½À´Ï´Ù. Ç÷¾× ÀûÇÕ¼º ÄÚÆÃ ¼Ö·ç¼ÇÀº ÀÇ·á±â±â¿¡¼­ Ç÷¾× ÀÀ°í¸¦ ¾ïÁ¦ÇÏ´Â µ¥ ÀÖ¾î ÀÇ·á ºÎ¹®À» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

»ýüÀûÇÕ¼º ÄÚÆÃ ¹× ±ÔÁ¦

±Þ°ÝÇÑ µµ½ÃÈ­¿Í ÇÔ²² À§»ý Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ¼ÒºñÀÚ ¹× °¡Á¤¿ë Á¦Ç°¿¡¼­ »ýü ÀûÇÕ¼º ÄÚÆÃ¿¡ ´ëÇÑ ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ȯÀÚÀÇ ¾ÈÀü°ú Á¦Ç° ǰÁúÀ» º¸ÀåÇϱâ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦¿Í Á¤ºÎÀÇ Á¶°ÇÀº »ýü ÀûÇÕ¼º ÄÚÆÃÀÇ µµÀÔÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¤ºÎ ±â°üÀÇ ±ÔÁ¦´Â ÀÇ·á±â±â Á¦Á¶¾÷ü°¡ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» ÁؼöÇϰí Á¦Ç°ÀÌ ½ÂÀÎµÇ°í »ó¿ëÈ­µÇ±â Àü¿¡ »ýü ÀûÇÕ¼º º¸ÁõÀ» Á¦°øÇϵµ·Ï °­Á¦Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á °ü·Ã °¨¿°(HAI)Àº ȯÀÚÀÇ Áõ»óÀ» ¾ÇÈ­½Ã۰í, ÀÇ·áºñ Áõ°¡, Àå±âÀûÀÎ Á¤½ÅÀû ¿Ü»ó ¹× ´õ ½É°¢ÇÑ °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¸ç, EMA ¹× FDA¿Í °°Àº ¼¼°è Á¤ºÎ ±â°üÀº Ä¡·áÀÇ ¾ÈÀü¼ºÀ» ¿ì¼±½ÃÇϰí Á¦Á¶µÈ ÀÇ·á±â±â°¡ »ýü ÀûÇÕ¼º ±âÁØÀ» ÃæÁ·Çϵµ·Ï Çϴ ƯÁ¤ ±ÔÁ¦¸¦ ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù. Ç×±Õ ÄÚÆÃÀº º´¿ø±Õ°ú ½Î¿ì°í °¨¿°ÀÇ ÀüÆÄ¸¦ ¾ïÁ¦ÇÏ´Â µ¥ ¸Å¿ì È¿°úÀûÀÔ´Ï´Ù.

ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö¸é¼­ Á¤ºÎ ±â°üÀº ÀÇ·á¿ë ºÎǰ °³¹ß¿¡ ¾ö°ÝÇÑ °¡À̵å¶óÀÎÀ» Àû¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â¿¡ »ýü ÀûÇÕ¼º ±âÁØÀ» Àû¿ëÇÔÀ¸·Î½á ±â¾÷Àº ±ÔÁ¦¸¦ ÃæÁ·Çϱâ À§ÇÑ Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» °³¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î Á¤ºÎÀÇ ±ÔÁ¦´Â ´õ ¸¹Àº ÀÇ·á °ü·Ã ±â¾÷µéÀÌ È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» ¸¸µé±â À§ÇØ °æÀïÇϰí, ºÎ°úµÈ Á¶°ÇÀ» ´Þ¼ºÇϱâ À§ÇØ ±â¼ú Çõ½ÅÀ» ÃËÁøÇÔÀ¸·Î½á °Å´ëÇÑ ½ÃÀå ÀáÀç·ÂÀ» âÃâÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ ¼¼°èÀûÀ¸·Î ¸¶½ºÅ©¿Í ÀÇ·á Á¦Ç° ºÎÁ·ÀÌ ½É°¢ÇØÁö¸é¼­ ¼¼°è °ø±Þ¸Á¿¡ Å« È¥¶õÀÌ »ý°å½À´Ï´Ù. ȯÀÚ¸¦ Àû±ØÀûÀ¸·Î Ä¡·áÇϱâ À§Çؼ­´Â ÀÇ·á Àåºñ°¡ ÇʼöÀûÀÌ¸ç º´¿ø Àüü°¡ ½É°¢ÇÑ ¿ì·Á¸¦ Á¦±âÇß½À´Ï´Ù. »ýü ÀûÇÕ¼º ÄÚÆÃÀÇ µµÀÔÀº ´õ ¸¹Àº ÀÇ·á±â±â ¹× ÀåÄ¡ Á¦Á¶¿¡ ÀÌ ±â¼úÀ» Ȱ¿ëÇÏ¿© ÀÇ·á ¿ëµµ¿¡ Å« Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. °ü·Ã Àç·á¸¦ »ç¿ëÇÑ »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀåÀº Æø¹ßÀûÀ¸·Î È®ÀåµÇ¾î ´Ù¾çÇÑ ÀÇ·á ¼¼ºÐÈ­¿¡¼­ °æÇèÀ» ½×À» ¼ö ÀÖ´Â ÁÁÀº ±âȸ¸¦ âÃâÇß½À´Ï´Ù. Äڷγª19 »çÅ·ΠÀÎÇØ »ýüÀûÇÕ¼º ÀÇ·á±â±â¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö¸é¼­ ÀÇ·á »ê¾÷ÀÌ È£È²À» ´©·È½À´Ï´Ù. ÀÌ·Î ÀÎÇØ »ýü ÀûÇÕ¼º ÄÚÆÃ »ê¾÷Àº ÃÖ´ë ¼öÁØÀÇ ¼öÀÍÀ» âÃâÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ

·¯½Ã¾ÆÀÇ ¿ìÅ©¶óÀ̳ª ÇÕº´Àº ¼¼°è º¸°Ç À§±â¸¦ ÃÊ·¡Çß°í, ¸·´ëÇÑ »ç¸ÁÀÚ, ³­¹Î, ÀüÀï ÇÇÇØÀÚ¸¦ Áö¿øÇÒ ÀÚ±Ý ºÎÁ·À¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿î »óȲ¿¡µµ ºÒ±¸Çϰí, ÀÌ¿ô ±¹°¡¿Í ¼±Áø±¹ÀÇ ÀÇ·á Àåºñ¿Í ÀǾàǰ µîÀÇ Áö¿øÀº ¿ìÅ©¶óÀ̳ª¿¡ ¸Å¿ì Áß¿äÇÑ ¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä ÃæÁ·¿¡ ´ëÇÑ ¿ä±¸´Â »ýü ÀûÇÕ¼º ÀÇ·á±â±â ¹× ½Äǰ Æ÷Àå Á¦Ç°ÀÇ »ý»êÀ» Áõ°¡½ÃÄ×°í, °á±¹ ¼¼°èÀûÀ¸·Î »ýü ÀûÇÕ¼º ÄÚÆÃÁ¦ ½ÃÀåÀ¸·Î À̾îÁ³½À´Ï´Ù. ½ÃÀå ±âȸ´Â »ýü ÀûÇÕ¼º ÄÚÆÃÀ» Æ÷ÇÔÇÑ ´Ù¾çÇÑ ÀÇ·á ºÎ¹®¿¡¼­ ´«¿¡ ¶ç°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ¼¼°è »ýüÀûÇÕ¼º ÄÚÆÃ ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ½ÃÀå ¿ªÇÐ, ÁÖ¿ä ±â¾÷ ÇöȲ ¹× Àü¸Á µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÇÁ·ÎÁ§Æ®ÀÇ ¹üÀ§¿Í Á¤ÀÇ

Á¦3Àå »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦4Àå ·¯½Ã¾Æ¡¤¿ìÅ©¶óÀ̳ª ÀüÀïÀÇ ¿µÇâ

Á¦5Àå ÁÖ¿ä ¿ä¾à

Á¦6Àå °í°´ÀÇ ¼Ò¸®

  • ½ÃÀå ÀÎÁöµµ¿Í Á¦Ç° Á¤º¸
  • ºê·£µå ÀÎÁöµµ¿Í ·Î¿­Æ¼
  • ±¸ÀÔ °áÁ¤¿¡¼­ °í·ÁµÇ´Â ¿ä¼Ò
  • ±¸ÀÔ ºóµµ
  • ±¸ÀÔ ¸Åü

Á¦7Àå »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀå Àü¸Á(2016³â-2030³â)

  • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • ±Ý¾×
    • ¼ö·®
  • À¯Çüº°
    • Ç÷¾× ÀûÇÕ¼º ÄÚÆÃ
    • Ç×±Õ ÄÚÆÃ
    • ÇÁ¸®¹Í½º ÄÚÆÃ(°ð¹Ù·Î »ç¿ëÇÒ ¼ö ÀÖ´Ù)
    • ±âŸ
  • µî±Þº°
    • ÀÇ·á µî±Þ
    • ½Äǰ µî±Þ
    • ·¹¹ö·¯Å丮 µî±Þ
  • Àç·áº°
    • ¼¼¶ó¹Í
    • Æú¸®¸Ó
    • ±Ý¼Ó¡¤ÇÕ±Ý
    • ±âŸ
  • ÃÖÁ¾»ç¿ëÀÚº°
    • ÀÇ·á »ê¾÷
    • ½Äǰ ¹× À½·á
    • ±âŸ
  • Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ³²¹Ì
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀå Á¡À¯À² : ±â¾÷º°(2022³â)

Á¦8Àå »ýü ÀûÇÕ¼º ÄÚÆÃ ½ÃÀå Àü¸Á : Áö¿ªº°(2016³â-2030³â)

  • ºÏ¹Ì
    • ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø
    • À¯Çüº°
    • µî±Þº°
    • Àç·áº°
    • ÃÖÁ¾»ç¿ëÀÚº°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ·¯½Ã¾Æ
    • ³×´ú¶õµå
    • ½ºÆäÀÎ
    • ÅÍŰ
    • Æú¶õµå
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Àεµ
    • Áß±¹
    • ÀϺ»
    • È£ÁÖ
    • º£Æ®³²
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹

Á¦9Àå °ø±ÞÃø ºÐ¼®

  • »ý»ê´É·Â : ±â¾÷º°
  • »ý»ê : ±â¾÷º°
  • ¿µ¾÷ È¿À² : ±â¾÷º°
  • ÁÖ¿ä °øÀå ¼ÒÀçÁö(ÃÖ´ë 25)

Á¦10Àå ½ÃÀå ¸ÅÇÎ(2022³â)

  • ¸ðµ¨º°
  • ¿ëµµº°
  • ÃÖÁ¾»ç¿ëÀÚº°
  • Áö¿ªº°

Á¦11Àå °Å½Ãȯ°æ°ú »ê¾÷ ±¸Á¶

  • ¼ö±Þ ºÐ¼®
  • ¼öÃâÀÔ ºÐ¼® - ¼ö·®°ú ±Ý¾×
  • °ø±Þ/¹ë·ùüÀÎ ºÐ¼®
  • PESTEL ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®

Á¦12Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ(°úÁ¦, ¼ºÀå ¾ïÁ¦¿äÀÎ)

Á¦13Àå ÁÖ¿ä ±â¾÷ »óȲ

  • ¸¶ÄÏ ¸®´õ ÁÖ¿ä 5°³»ç °æÀï ¸ÅÆ®¸¯½º
  • ¸¶ÄÏ ¸®´õ ÁÖ¿ä 5°³»ç ½ÃÀå ¸ÅÃ⠺м®(2022³â)
  • ÀμöÇÕº´(M&A)/ÇÕº´»ç¾÷(ÇØ´çÇÏ´Â °æ¿ì)
  • SWOT ºÐ¼®(½ÃÀå ÁøÃâ±â¾÷ 5°³»ç)
  • ƯÇ㠺м®(ÇØ´çÇÏ´Â °æ¿ì)

Á¦14Àå °¡°Ý ºÐ¼®

Á¦15Àå »ç·Ê ¿¬±¸

Á¦16Àå ÁÖ¿ä ±â¾÷ Àü¸Á

  • Covalonoem Technologies
  • DSM Biomedical
  • SurModics, Inc.
  • Carmeda AB
  • Specialty Coating Systems Inc.
  • Elkem
  • Evonik
  • Medtronic
  • Hydromer Inc.
  • Innovative Surface Technologies

Á¦17Àå Àü·«Àû Ãßõ »çÇ×

Á¦18Àå ´ç»ç¿¡ ´ëÇØ, ¸éÃ¥»çÇ×

LSH 23.10.10

Global biocompatible coatings market size was valued at USD 15.4 billion in 2022, which is expected to reach USD 41.2 billion in 2030, with a CAGR of 13.1% for the forecast period between 2023 and 2030. Biocompatible coating emphasizes developing coating technologies, which are required in the medical devices sector which is expected to incur major development in the coming years. With the concern of patient safety biocompatible coatings become crucial in enhancing the functionality and biocompatibility of medical devices, implants, and prominent equipment.

Biocompatible coatings are used for imparting antimicrobial activities using development of cementless hydroxyapatite (HA)-coated titanium orthopedic prostheses. Hemocompatible coatings are significantly related to thrombogenic and thromboembolic complications where the coating is applied on medical-grade materials. Hemocompatible coatings comprises of active and passive types which have their specific characteristics. Ceramic oxide coatings for biomedical purposes are extensively used for damaged bone tissue and joint replacement. Aumina and zirconia are suitable ceramic materials used, because of their unique characteristics such as excellent wear resistance and biocompatibility. The progressive drivers for biocompatible coatings materials carry enormous potential for global market and create massive opportunities to expand in different segmentation.

Growth in Hemocompatible Coatings

Hemocompatible has high tolerance with blood, which is associated to thrombogenic and thromboembolic complications induced by biomaterial surfaces. Commercial products in the market products possess inadequate hemocompatibility for application in the medical grade. Hemocompatible coating solutions are tremendously driving the medical sector in inhibiting blood coagulation on the medical device. Health-driven companies are significantly producing such effective devices using biocompatible coatings, creating huge market opportunities as the technology requires prominent usage of materials.

Surmodics's proprietary PhotoLink UV curing technology can successfully develop coatings for all medical-grade materials using light-activated chemistry that generate bonds rapidly. Their exceptional coating solutions can easily integrate into existing manufacturing systems and enhance medical device functioning. Active (heparin) and passive (non-heparin) hemocompatible coatings inhibit thrombin generation and reduce protein adsorption. The significance of biocompatible coatings can be explored in different medical devices which will open global market opportunities by introducing more innovations for such coatings.

Biocompatible Coatings and Regulations

Rapid urbanization along with demand for hygienic products has raised concerns which is driving the market demand for biocompatible coatings in consumer and household products. Stringent regulations and government conditions on ensuring patient safety and product quality encourages to implement biocompatible coatings. Regulations by government entities have bounded medical device manufacturers to adhere stringent guidelines and provide assurance about biocompatibility before products can be approved and commercialized. Healthcare-associated infections (HAIs) can exacerbate the patient's conditions, increasing healthcare costs, prolonged mental trauma, and more severe outcomes. Global government agencies like European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have created specific regulations that prioritize safety in treatments and ensure manufactured medical devices should meet the biocompatibility standards. Antibacterial coatings are highly effective in combating pathogens and restricting the transmission of infections.

The rising concerns for patient safety is forcing government agencies to incorporate stringent guidelines for developing medical grade components. Applying biocompatibility standards on such devices encourages companies to generate innovative solutions to meet the regulations. Consequently, government regulations can also create huge market potential as more medical companies compete to generate effective solutions and drive innovation in achieving the imposed conditions.

Impact of COVID-19

The COVID-19 pandemic severely led to shortage of masks and healthcare products across the globe and global supply chain was prominently disrupted. The indispensable need for medical devices was serious concerns across the hospitals to provide active patient treatment. Incorporation of biocompatible coatings significantly revolutionized medical applications by utilizing the technology in building more medical devices and equipment. The market for biocompatible coating using relevant materials exploded and generated excellent opportunities to gain experience in various medical segmentation. The pandemic time was a boom for medical industries by increasing requirement of biocompatible medical devices which has created immense potential for building devices that biocompatible norms must regulate. This has taken the biocompatible coating industry to the utmost level of revenue generation.

Impact of Russia-Ukraine War

The annexation of Russia on Ukraine has sparked global health crises which led to enormous decease, displacement of people, and lack in sufficient funds to support people affected from the war. Despite the prevailing difficulties, aid from other neighboring and developed countries such as medical devices, useful medicines, etc. has significantly became crucial for Ukraine. The demand to fulfill the needs has increased the production of biocompatible medical devices and food packaged products which ultimately derived the biocompatible coatings market across the globe. The market opportunities have grown prominently in various health care sectors including biocompatible coatings.

Key Players Landscape and Outlook

The advancement in biocompatible coating technologies has prominently gained interest to incorporate in various medical applications such as device-based therapies, blood-contacted equipment, etc. Evonik has successfully commenced proprietary surface modification technology called Endexo, which is based on low molecular weight fluoro-oligomers which significantly assist in enhancing the biocompatibility of medical devices making direct contact with blood, tissue, and other body fluids. It possesses surface modifying characteristics that impart permanent and durable modification of surface properties without altering or impacting the device dimensions or its functionality. Surface modification using Endexo biocompatible coating technology can effectively reduce around 99% platelet adhesion and thrombus formation from blood contacting-devices such as vascular stents, catheters, etc. The importance of biocompatible coating technologies in medical applications can be recognized which has immense potential for global market to grow non-linearly.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Biocompatible coatings Market

4. Impact of Russia-Ukraine War

5. Executive Summary

6. Voice of Customer

  • 6.1. Market Awareness and Product Information
  • 6.2. Brand Awareness and Loyalty
  • 6.3. Factors Considered in Purchase Decision
    • 6.3.1. Brand Name
    • 6.3.2. Quality
    • 6.3.3. Quantity
    • 6.3.4. Price
    • 6.3.5. Product Specification
    • 6.3.6. Application Specification
    • 6.3.7. Shelf-life
    • 6.3.8. Availability of Product
  • 6.4. Frequency of Purchase
  • 6.5. Medium of Purchase

7. Biocompatible Coatings Market Outlook, 2016-2030F

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
    • 7.1.2. By Volume
  • 7.2. By Type
    • 7.2.1. Hemocompatible Coatings
      • 7.2.1.1. Active
      • 7.2.1.2. Passive
    • 7.2.2. Antibacterial Coatings
      • 7.2.2.1. Antibiotics-releasing
      • 7.2.2.2. Antibiotics-graft
      • 7.2.2.3. Silver-containing
      • 7.2.2.4. Others
    • 7.2.3. Pre-Mixed Coatings (ready-to-use)
    • 7.2.4. Others
  • 7.3. By Grade
    • 7.3.1. Medical Grade
    • 7.3.2. Food Grade
    • 7.3.3. Lab Grade
  • 7.4. By Materials
    • 7.4.1. Ceramics
    • 7.4.2. Polymers
    • 7.4.3. Metals & Alloys
    • 7.4.4. Others
  • 7.5. By End-user
    • 7.5.1. Healthcare Industry
      • 7.5.1.1. Medical Devices
      • 7.5.1.2. Pharmaceutical Drugs
    • 7.5.2. Food & Beverage
    • 7.5.3. Others
  • 7.6. By Region
    • 7.6.1. North America
    • 7.6.2. Europe
    • 7.6.3. South America
    • 7.6.4. Asia-Pacific
    • 7.6.5. Middle East and Africa
  • 7.7. By Company Market Share (%), 2022

8. Biocompatible coatings Market Outlook, By Region, 2016-2030F

  • 8.1. North America*
    • 8.1.1. Market Size & Forecast
      • 8.1.1.1. By Value
      • 8.1.1.2. By Volume
    • 8.1.2. By Type
      • 8.1.2.1. Hemocompatible Coatings
      • 8.1.2.1.1. Active
      • 8.1.2.1.2. Passive
      • 8.1.2.2. Antibacterial Coatings
      • 8.1.2.2.1. Antibiotics-releasing
      • 8.1.2.2.2. Antibiotics-graft
      • 8.1.2.2.3. Silver-containing
      • 8.1.2.2.4. Others
      • 8.1.2.3. Pre-Mixed Coatings (ready-to-use)
      • 8.1.2.4. Others
    • 8.1.3. By Grade
      • 8.1.3.1. Medical Grade
      • 8.1.3.2. Food Grade
      • 8.1.3.3. Lab Grade
    • 8.1.4. By Materials
      • 8.1.4.1. Ceramics
      • 8.1.4.2. Polymers
      • 8.1.4.3. Metals & Alloys
      • 8.1.4.4. Others
    • 8.1.5. By End-user
      • 8.1.5.1. Healthcare Industry
      • 8.1.5.1.1. Medical Devices
      • 8.1.5.1.2. Pharmaceutical Drugs
      • 8.1.5.2. Food & Beverage
      • 8.1.5.3. Others
    • 8.1.6. United States*
      • 8.1.6.1. Market Size & Forecast
      • 8.1.6.1.1. By Value
      • 8.1.6.1.2. By Volume
      • 8.1.6.2. By Type
      • 8.1.6.2.1. Hemocompatible Coatings
      • 8.1.6.2.1.1. Active
      • 8.1.6.2.1.2. Passive
      • 8.1.6.2.2. Antibacterial Coatings
      • 8.1.6.2.2.1. Antibiotics-releasing
      • 8.1.6.2.2.2. Antibiotics-graft
      • 8.1.6.2.2.3. Silver-containing
      • 8.1.6.2.2.4. Others
      • 8.1.6.2.3. Pre-Mixed Coatings (ready-to-use)
      • 8.1.6.2.4. Others
      • 8.1.6.3. By Grade
      • 8.1.6.3.1. Medical Grade
      • 8.1.6.3.2. Food Grade
      • 8.1.6.3.3. Lab Grade
      • 8.1.6.4. By Materials
      • 8.1.6.4.1. Ceramics
      • 8.1.6.4.2. Polymers
      • 8.1.6.4.3. Metals & Alloys
      • 8.1.6.4.4. Others
      • 8.1.6.5. By End-user
      • 8.1.6.5.1. Healthcare Industry
      • 8.1.6.5.1.1. Medical Devices
      • 8.1.6.5.1.2. Pharmaceutical Drugs
      • 8.1.6.5.2. Food & Beverage
      • 8.1.6.5.3. Others
    • 8.1.7. Canada
    • 8.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 8.2. Europe
    • 8.2.1. Germany
    • 8.2.2. France
    • 8.2.3. Italy
    • 8.2.4. United Kingdom
    • 8.2.5. Russia
    • 8.2.6. Netherlands
    • 8.2.7. Spain
    • 8.2.8. Turkey
    • 8.2.9. Poland
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
  • 8.4. Asia-Pacific
    • 8.4.1. India
    • 8.4.2. China
    • 8.4.3. Japan
    • 8.4.4. Australia
    • 8.4.5. Vietnam
    • 8.4.6. South Korea
    • 8.4.7. Indonesia
    • 8.4.8. Philippines
  • 8.5. Middle East & Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. South Africa

9. Supply Side Analysis

  • 9.1. Capacity, By Company
  • 9.2. Production, By Company
  • 9.3. Operating Efficiency, By Company
  • 9.4. Key Plant Locations (Up to 25)

10. Market Mapping, 2022

  • 10.1. By Model
  • 10.2. By Application
  • 10.3. By End-user
  • 10.4. By Region

11. Macro Environment and Industry Structure

  • 11.1. Supply Demand Analysis
  • 11.2. Import Export Analysis - Volume and Value
  • 11.3. Supply/Value Chain Analysis
  • 11.4. PESTEL Analysis
    • 11.4.1. Political Factors
    • 11.4.2. Economic System
    • 11.4.3. Social Implications
    • 11.4.4. Technological Advancements
    • 11.4.5. Environmental Impacts
    • 11.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 11.5. Porter's Five Forces Analysis
    • 11.5.1. Supplier Power
    • 11.5.2. Buyer Power
    • 11.5.3. Substitution Threat
    • 11.5.4. Threat from New Entrant
    • 11.5.5. Competitive Rivalry

12. Market Dynamics

  • 12.1. Growth Drivers
  • 12.2. Growth Inhibitors (Challenges, Restraints)

13. Key Players Landscape

  • 13.1. Competition Matrix of Top Five Market Leaders
  • 13.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 13.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 13.4. SWOT Analysis (For Five Market Players)
  • 13.5. Patent Analysis (If Applicable)

14. Pricing Analysis

15. Case Studies

16. Key Players Outlook

  • 16.1. Covalonoem Technologies
    • 16.1.1. Company Details
    • 16.1.2. Key Management Personnel
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As reported)
    • 16.1.5. Key Market Focus & Geographical Presence
    • 16.1.6. Recent Developments
  • 16.2. DSM Biomedical
  • 16.3. SurModics, Inc.
  • 16.4. Carmeda AB
  • 16.5. Specialty Coating Systems Inc.
  • 16.6. Elkem
  • 16.7. Evonik
  • 16.8. Medtronic
  • 16.9. Hydromer Inc.
  • 16.10. Innovative Surface Technologies

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

17. Strategic Recommendations

18. About Us & Disclaimer

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦